In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hepion Pharmaceuticals, Inc.

https://hepionpharma.com/

Latest From Hepion Pharmaceuticals, Inc.

Finance Watch: SPAC Spree To Continue ‘For Foreseeable Future’

Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.

Financing Deals

Assembly Falls Well Short In Attempt At Finite HBV Therapy

Biotech tried to show that a core inhibitor combined with standard hepatitis B therapy could yield lasting benefit after treatment. Vebicorvir will continue to be studied as a chronic treatment in HBV.

Clinical Trials Business Strategies

Tech Transfer Roundup: Tonix Obtains Triple-Reuptake Inhibitor For PTSD From Wayne State

TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.

Commercial Deals

Pipeline Watch: Phase III Progress With BL-8040, Recorlev And Estelle

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Ciclofilin Pharmaceuticals, Inc.
    • ContraVir Pharmaceuticals, Inc.
UsernamePublicRestriction

Register